【53.ren327.top】

슬롯버프 ┥ 8.ren327.top ┥ 슬롯머신 게임

오션파라다이스 다운로드 ┥ 20.ren327.top ┥ 체리마스터 어플

사설바둑이 ┥ 60.ren327.top ┥ 알라딘온라인릴게임

릴게임 꽁머니 ┥ 84.ren327.top ┥ 릴게임설치

인터넷야마토릴게임 오션파라 다이스7 황금성게임어플 야마토예시 온라인릴게임 릴게임예시 카지노 슬롯머신 종류 바다이야기 무료게임 다운로드 바다이야기 노무현 바다이야기다운로드 고전릴게임 릴게임총판 프라그마틱 슬롯 사이트 우주전함야마토2202 최신야마토게임 릴게임종류 릴게임오션파라다이스 팡멀티릴게임 릴게임백경 바다이야기게임공략방법 릴게임먹튀검증 오리 지날야마토2게임 황금성게임공략법 릴게임 무료머니 릴게임5만릴게임사이다 한게임머니파는곳 슬롯 릴 게임 신천지인터넷게임 릴게임연타 오리지널바다이야기 게임몰릴게임 무료충전현금게임 종합 릴게임 바다이야기게임동영상 슬롯머신 추천 릴게임천국 골드몽게임 바다이야기오리지널 무료슬롯버프 릴게임 다빈치 릴게임 사이트 빠찡코 하는 방법 손오공게임하기 무료야마토 온라인야마토게임 바다이야기파일 온라인 야마토 게임 황금포카성 야마토게임기 모바일오션파라다이스7 무료황금성 바다 이야기 다운 우주전함야마토게임 바다이야기게임방법 골드몽 먹튀 황금성게임방법 릴게임무료 온라인 슬롯머신 황금성포커게임 파칭코종류 오션슬롯 주소 무료충전 바다이야기 바다이야기 먹튀사이트 바다이야기 pc 버전 무료충전게임 골드몽 먹튀 하이클래스릴게임 야마토오락실게임 바다이야기 먹튀 신고 황금성게임사이트 오리 지날황금성 야마토 게임방법 바다이야기7 온라인황금성주소 pc빠찡꼬게임 릴게임백경 바다이야기 도박 황금성오리지널 슬롯 게임사 추천 온라인백경게임 바다이야기 릴게임 사이트 추천 및 안내 오션슬롯 황금성게임종류 최신야마토게임 오리지널황금성3게임 카지노릴게임 우주전함야마토게임 오리지날야마토 무료바다이야기게임 카지노릴게임 바다이야기 노무현 야마토빠칭코 바다이야기 게임 릴게임신천지 무료인터넷게임 바다이야기게임하는곳 뉴야마토 우주전함 야마토게임 슬롯 머신 html 10원야마토게임 황금성게임사이트 바다이야기 게임 방법 황금성게임장 알라딘꽁머니 오리지날바다 슬롯 게시판 바다이야기도박 백경게임다운로드 바다이야기시즌5 10원야마토 종합 릴게임 황금성3게임공략법 손오공 릴게임 강원랜드 슬롯머신 잭팟 릴게임천국 바다이야기게임다운로드 빠찡코 하는 방법 야마토 빠칭코 백경게임예시 슬롯나라 오션파라다이스 온라인 신천지릴게임장주소 모바일릴게임 사설경정 알라딘릴게임다운로드 This article was released as Pharm Edaily Premium Content on June 4, 2025, at 7:41 AM.


[Kim Jiwan, Edaily Reporter] Naturalendo Tech, at the center of the 2015 “Fake Baeksoo” crisis, is making a comeback.
According to MP Doctor (formerly MarketPoint) by KG Zeroin, Naturalendo Tech’s stock closed at 2,800 KRW, up 19.91% (465 KRW) from the previous trading 포상 및 특이사항 day.
The Supreme Court ruled that the credibility of the announcement at the time was questionable. However, it also concluded that state institutions are not liable for compensating shareho 파산선고후 lders for the subsequent stock price collapse.



Cynanchum wilfordii. (Photo=Edaily DB)


On June 2, the First Division of t 알바모집인원0명 he Supreme Court (Presiding Justice Noh Tae-ak) finalized a ruling rejecting a damages lawsuit filed by 18 shareholders of Naturalendo Tech against the Korea Consumer Agency and the government. This m 기업은행바꿔드림론 arks the end of a five-year legal battle, with the Supreme Court upholding the lower court’s decision.
In April 2015, the Korea Consumer Agency announced that some Baeksoo products distribut 정기예금상품 ed in the market contained “Cynanchum auriculatum,” a plant ingredient potentially harmful to humans. Naturalendo Tech’s stock plummeted shortly after this announcement, dropping from around 86,000 KRW to 8,500 KRW in less than a month.
However, the Supreme Court pointed out that the agency did not clearly determine how much of the harmful substance was present in Naturalendo Tech‘s products or how it got there before making the announcement. There was also insufficient evidence that the company had intentionally used the ingredient.
“The Consumer Agency’s judgment that the company substituted Baeksoo with the cheaper Cynanchum auriculatum for cost-saving purposes lacked sufficient basis,” said the court. “The announcement could have created the impression that Naturalendo Tech’s products were broadly contaminated with harmful substances.”
Although the Supreme Court found the announcement to be factually inaccurate, it ruled that there was no clear causal link between the statement and the share price drop, thereby rejecting the shareholders’ damage claims.
The court explained, “The damage to reputation or trust in the product stems from the company itself. Economic losses suffered by shareholders due to a falling stock price are not legally compensable.”
NovaRex , Best-Ever Quarterly Export Performance
ODM health supplement firm NovaRex is riding a wave of optimism as its export momentum, especially to China, continues to strengthen. On the day, the company’s stock jumped 14.87% (2,290 KRW) to close at 17,690 KRW.



NovaRex’s new Osong plant. (Photo=NovaRex)


DS Investment & Securities analyst Jang Ji-hye stated, “NovaRex’s overseas sales are expected to reach 109.4 billion KRW in 2025, up 20% from last year. The rapid increase in orders from key Chinese clients and new customer acquisition are driving growth.”
The company’s overseas revenue share, which was only 7% in 2021, surged to 25% by 2023 and is expected to hit 34% this year.
Q1 2025 results support this trend. Export sales rose 85% year-on-year to 31.4 billion KRW, with China accounting for 24 billion KRW?a record high.
Jang added, “Rising demand in China, more orders from existing customers, new partnerships, favorable exchange rates, and cost control are expected to improve overall profitability.”
A NovaRex official commented, “Thanks to aggressive sales activities last year, we secured those clients and recorded record-breaking performance in Q4.”
DS Investment & Securities forecasts NovaRex will post 324.4 billion KRW in consolidated revenue and 26.9 billion KRW in operating profit this year up 9% and 16% year-on-year, respectively.
Inventage Lab’s, Confidence in Long-Acting Platform
Inventage Lab continues its upward momentum. The company‘s recent filing of a patent invalidation claim against a competitor, G2GBIO, is seen as a positive catalyst for its stock, which rose 6.97% (2,800 KRW) to close at 42,950 KRW.
On April 23, Inventage Lab filed with the Intellectual Property Trial and Appeal Board to invalidate G2GBIO’s patent for a sustained-release injection formulation of donepezil, a key component in Alzheimer’s treatment. The patent involves a microsphere-based system that prolongs drug release.4



Kim Joo-hee, CEO of Inventage Lab (Photo=Inventage Lab)


Both companies are developing long-acting injectable technologies. As long-acting formulations for chronic diseases such as obesity, hair loss, and dementia gain popularity for improving patient adherence, competition between the two is intensifying.
Inventage Lab’s platform is called IVL-DrugFluidic, while G2GBIO’s is InnoLAMP?both microsphere-based systems aiming to dramatically reduce injection frequency.
The legal challenge is viewed as part of Inventage Lab’s effort to gain a technical edge in the Alzheimer’s market. The company signed a development deal with Chong Kun Dang in 2022 for IVL3003, a once-monthly donepezil injection now in Phase 1/2 trials in Australia.
Meanwhile, G2GBIO is developing GB-5001 and its variants GB-5001A and GB-5001D. GB-5001A is in joint development with Korea Pharma and Huons. The drug received IND approval last year from the MFDS and has completed its Clinical Study Report (CSR).
A G2GBIO official said, “We have submitted a legal opinion to the Korea Exchange and our underwriter, indicating that Inventage Lab’s chances of winning are low.”
An industry insider noted, “This isn’t just a legal battle. it’s a strategic fight for leadership in the next-generation modified drug market. The outcome could significantly reshape the competitive landscape.”
김지완 (2pac@edaily.co.kr)